Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sandoz's Carol Lynch Highlights Decade Of Biosimilar Dominance And Plans For Many More Winning Years

Executive Summary

2016 marks the 10 year anniversary of the first biosimilar approval in Europe, Sandoz Inc.'s Omnitrope (somatropin), but only the first anniversary for approval of a biologic copycat drug in the US – a country that has been slow to embrace the concept. Sandoz's global head of biopharmaceuticals and oncology, Carol Lynch, explains to Scrip how the biosimilars market has developed over the last decade and what the biggest challenges have been along the way.

Advertisement

Related Content

Sandoz Extrapolates Biosimilar Rituximab Data For EU Filing
Court Probes Rationale Of Biosimilars' 180-Day Notice

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065129

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel